Biomerica
Open
$2.41
Prev. Close
$2.41
High
$2.41
Low
$2.38
Market Snapshot
$7.07M
-1.7
-2.25
$5.58M
53
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. The firm develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 53 full-time employees. The firm develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.
Recently from Cashu
Please provide the text you'd like me to summarize.
Sure! Please provide the text you'd like me to summarize.
Please provide the content you would like summarized.
Sure! Please provide the text you'd like me to summarize.
Biomerica Stock Analysis: Key Insights and Market Trends
Please provide the text you would like me to summarize, and I'll be happy to help!
Biomerica Expands Diagnostic Portfolio with Innovative Testing Solutions for Healthcare Enhancement
Biomerica Expands Diagnostic Portfolio with Innovative Testing Solutions Biomerica, a leader in the development of advanced diagnostic tests, announces the expansion of its product offerings to includ…